Hematologic and nonhematologic abnormalities during treatment with imatinib
| Parameter and grade4-150 . | All enrolled patients, N = 56 no. (%) . |
|---|---|
| Anemia | |
| Grade 3 | 17 (30) |
| Grade 4 | 4 (7) |
| Thrombocytopenia | |
| Grade 3 | 12 (21) |
| Grade 4 | 15 (27) |
| Leukocytopenia | |
| Grade 3 | 15 (27) |
| Grade 4 | 23 (41) |
| Neutrocytopenia | |
| Grade 3 | 7 (13) |
| Grade 4 | 30 (54) |
| Alkaline phosphatase increase | |
| Grade 3 | 1 (2) |
| Grade 4 | 0 |
| ALT increase | |
| Grade 3 | 2 (4) |
| Grade 4 | 0 |
| Bilirubin increase | |
| Grade 3 | 2 (4) |
| Grade 4 | 0 |
| Parameter and grade4-150 . | All enrolled patients, N = 56 no. (%) . |
|---|---|
| Anemia | |
| Grade 3 | 17 (30) |
| Grade 4 | 4 (7) |
| Thrombocytopenia | |
| Grade 3 | 12 (21) |
| Grade 4 | 15 (27) |
| Leukocytopenia | |
| Grade 3 | 15 (27) |
| Grade 4 | 23 (41) |
| Neutrocytopenia | |
| Grade 3 | 7 (13) |
| Grade 4 | 30 (54) |
| Alkaline phosphatase increase | |
| Grade 3 | 1 (2) |
| Grade 4 | 0 |
| ALT increase | |
| Grade 3 | 2 (4) |
| Grade 4 | 0 |
| Bilirubin increase | |
| Grade 3 | 2 (4) |
| Grade 4 | 0 |
Abnormalities occurring during treatment or worsening from baseline to the indicated grade according to the NCI/NIH Common Toxicity Criteria.